#1 Clinical Trials Search in Europe

Sodium Dihydrogen Phosphate Dihydrate

This article explores the use of Sodium Dihydrogen Phosphate Dihydrate in clinical trials for two distinct medical areas: blood cancer treatment and cardiac surgery. The first trial investigates a new drug called MP0533 for patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The second trial compares different types of cardioplegia solutions, including one containing Sodium Dihydrogen Phosphate Dihydrate, in patients undergoing major heart surgery. These studies aim to improve treatment options and outcomes for patients with these serious medical conditions.

Table of Contents

What is Sodium Dihydrogen Phosphate Dihydrate?

Sodium Dihydrogen Phosphate Dihydrate (SDPD) is a chemical compound used in various medical applications. It’s important to note that this substance is often used in combination with other compounds in medical formulations[1]. SDPD is a type of phosphate salt, which plays crucial roles in many bodily functions, including maintaining proper pH balance and supporting bone health.

Medical Uses

SDPD is utilized in several medical contexts:

  • Cancer Treatment: It’s being studied as part of a novel treatment for blood cancers, specifically relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)[1].
  • Cardioplegia Solutions: SDPD is a component in solutions used during heart surgeries to temporarily stop the heart, protecting it during procedures[2].

Current Clinical Trials

SDPD is currently being investigated in clinical trials:

  • Blood Cancer Treatment: A phase 1/2a trial is studying MP0533, a drug containing SDPD, for patients with relapsed or refractory AML or MDS. This trial aims to determine the safety, tolerability, and preliminary effectiveness of the treatment[1].
  • Cardiac Surgery: Another study is comparing different types of cardioplegia solutions, including one containing SDPD, in patients undergoing major cardiac surgery with extracorporeal circulation[2].

Administration

The administration of SDPD varies depending on its use:

  • Cancer Treatment: In the MP0533 trial, it’s part of a solution for infusion, likely administered intravenously[1].
  • Cardiac Surgery: As part of a cardioplegia solution, it’s administered directly to the heart during surgery, often through antegrade epicardial coronary artery infusion[2].

Potential Side Effects

As SDPD is often used in combination with other substances, side effects can vary. In the context of the ongoing clinical trials:

  • Cancer Treatment Trial: Potential side effects are being closely monitored. These may include changes in blood cell counts, infections, and effects on liver and kidney function[1].
  • Cardiac Surgery: Side effects related to the use of cardioplegia solutions may include heart rhythm disturbances, kidney problems, or bleeding. However, these are often related to the surgery itself rather than the specific solution used[2].

Patient Considerations

If you’re considering participating in a clinical trial or undergoing a procedure involving SDPD:

  • Discuss all potential risks and benefits with your healthcare provider.
  • Inform your doctor about all medications you’re taking and any existing health conditions.
  • For cancer trials, be aware of eligibility criteria, which may include factors like age, cancer type, and previous treatments[1].
  • For cardiac surgery, discuss the type of cardioplegia solution that will be used and any specific considerations for your case[2].

Remember, SDPD is typically one component of a larger treatment approach. Your healthcare team will consider your individual needs when determining the most appropriate treatment plan.

Aspect Blood Cancer Trial Cardiac Surgery Trial
Main Drug/Intervention MP0533 (containing Sodium Dihydrogen Phosphate Dihydrate) Custodiol crystalloid cardioplegia vs. Buckberg blood cardioplegia
Target Condition Relapsed/Refractory AML or MDS Major cardiac surgery with extracorporeal circulation
Primary Objectives Safety, tolerability, and preliminary anti-leukemic activity Non-inferiority of Custodiol vs. Buckberg cardioplegia
Key Inclusion Criteria Age ≥18, R/R AML or MDS/AML diagnosis Age >18, indication for major cardiac surgery
Primary Endpoints Adverse events, laboratory changes, overall response rate Composite of death, perioperative AMI, low cardiac output, acute kidney failure
Secondary Endpoints Pharmacokinetics, survival measures, response duration Troponin levels, mortality, bleeding events, neurological complications

FAQ

  • What is Sodium Dihydrogen Phosphate Dihydrate used for in these clinical trials? In these trials, Sodium Dihydrogen Phosphate Dihydrate is used as an ingredient in two different medical applications. In the first trial, it's part of a new drug called MP0533 being tested for blood cancer treatment. In the second trial, it's an ingredient in a cardioplegia solution used during heart surgery to protect the heart.
  • What types of blood cancer are being studied in the first trial? The first trial is studying relapsed or refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These are serious blood cancers that have either come back after treatment or haven't responded well to previous treatments.
  • What is the main goal of the cardiac surgery trial? The main goal of the cardiac surgery trial is to compare two types of cardioplegia solutions: Custodiol crystalloid cardioplegia and Buckberg blood cardioplegia. The study aims to show that Custodiol is not inferior to Buckberg in protecting the heart during major cardiac surgery with prolonged aortic clamping times.
  • Who can participate in these clinical trials? For the blood cancer trial, patients must be 18 years or older with a diagnosis of R/R AML or R/R MDS/AML. For the cardiac surgery trial, participants must be over 18 years old and have a cardiac condition requiring major cardiac surgery with extracorporeal circulation and aortic clamping.
  • What are some of the main outcomes being measured in these trials? In the blood cancer trial, researchers are looking at the safety and effectiveness of MP0533, including side effects and response rates. In the cardiac surgery trial, they're measuring outcomes such as death, heart attack, kidney failure, and the need for certain medications after surgery. Both trials are also monitoring various safety parameters and quality of life measures.

Ongoing Clinical Trials on Sodium Dihydrogen Phosphate Dihydrate

  • A study to evaluate the safety of VTx-002 in patients with amyotrophic lateral sclerosis.

    Recruiting

    2 1 1
    Investigated drugs:
    Belgium The Netherlands Spain

  • A Study Testing the Safety and How Well GTX-102 Works in Adults and Children with Angelman Syndrome

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Portugal

  • Study on the Long-Term Safety of GTX-102 for Patients with Angelman Syndrome

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Spain

  • Study on the Effects of Custodiol and Buckberg Cardioplegia in Patients Undergoing Major Heart Surgery with Prolonged Aortic Clamping

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Spain

  • Study on the Effects of GTX-102 for Children with Angelman Syndrome

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Germany The Netherlands Poland Spain

Glossary

  • Acute Myeloid Leukemia (AML): A type of blood cancer that starts in the bone marrow and quickly moves into the blood. It affects the myeloid cells, which normally develop into various types of blood cells.
  • Myelodysplastic Syndrome (MDS): A group of disorders where the bone marrow doesn't produce enough healthy blood cells. It can sometimes progress to acute myeloid leukemia.
  • Relapsed/Refractory (R/R): In cancer treatment, 'relapsed' means the cancer has returned after a period of improvement, while 'refractory' means the cancer hasn't responded well to treatment.
  • Cardioplegia: A solution used to stop the heart temporarily during heart surgery. It helps protect the heart muscle from damage while the surgeon works on it.
  • Extracorporeal Circulation: A technique used in heart surgery where a machine temporarily takes over the function of the heart and lungs, allowing surgeons to operate on a still, bloodless heart.
  • Aortic Clamping: A surgical technique where the aorta (the main artery from the heart) is temporarily clamped to stop blood flow during heart surgery.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Troponin I US: A highly sensitive marker of heart muscle damage, often measured to detect heart attacks or assess heart health after surgery.
  • AKIN-III Acute Kidney Failure: A severe stage of sudden kidney failure, classified according to the Acute Kidney Injury Network (AKIN) criteria.
  • Ionotropic Drugs: Medications that change the force of heart muscle contractions. They're often used to support heart function after surgery.

References

  1. http://clinicaltrials.eu/trial/study-of-mp0533-for-patients-with-relapsed-or-refractory-acute-myeloid-leukemia-or-myelodysplastic-syndrome-using-sodium-dihydrogen-phosphate-dihydrate-polysorbate-20-and-sodium-chloride/
  2. http://clinicaltrials.eu/trial/study-on-the-effects-of-custodiol-and-buckberg-cardioplegia-in-patients-undergoing-major-heart-surgery-with-prolonged-aortic-clamping/